-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the topic of price increase of traditional Chinese medicine products has been hotly debated
.
Not long ago, Beijing Tongrentang issued a price adjustment notice.
The selling price of Angong Niuhuang Pills (3 g × 1 pill/box) rose from 780 yuan to 860 yuan, a price increase of about 10%, and the implementation began on December 1
.
According to industry sources, this is the third time that Tongrentang has publicly adjusted the price of Angong Niuhuang Wan in the past 20 years
.
In 2012, the price of Angong Niuhuang Wan produced by Tongrentang increased by 60%, from 350 yuan to 560 yuan; in December 2019, Tongrentang Angong Niuhuang Wan increased from 560 yuan to 780 yuan, an increase of about 40%
.
Regarding the reason for the price increase this time, Beijing Tongrentang told the relevant media that the main reason is that the price of raw materials for the production of Angong Niuhuang Wan has been rising, coupled with labor costs, so the overall price of the product has also risen
.
It is worth mentioning that not long after the news of the price increase of Angong Niuhuang Pills, another Chinese medicine giant also announced that its Angong Niuhuang Pills had increased the price
.
On December 13, China Resources Sanjiu replied to investors on the interactive platform that due to the continuous increase in overall costs in recent years and other reasons, the ex-factory price of the company's Angong Niuhuang Wan has increased this year
.
Some industry analysts pointed out that Angong Niuhuang Wan consists of 11 medicinal materials.
The main raw materials include bezoar, musk, pearl, cinnabar, realgar, coptis, yellow census, gardenia, turmeric, borneol and buffalo horn concentrate powder
.
Relevant statistics show that among the 11 raw materials mentioned above, 7 have increased their prices in the past year
.
Among them, the price increase of huanglian and turmeric is more than 30%
.
"Bezoar and musk are still rare and precious materials
.
The precious medicinal materials have been soaring in recent years.
At present, 1g of natural bezoar is about 500 yuan, and 1g of natural musk is about 400 yuan, which is equivalent to 400,000-500,000 per kilogram.
The sky-high price above RMB yuan
.
” This person believes that from the perspective of the composition of medicinal materials, the overall increase in product prices caused by the increase in raw material prices is also expected
.
In addition to Angong Niuhuang Pills, in May this year, Pien Tze Huang also raised the price of Pien Tze Huang products, mainly because of the increase in cost prices and the use of limited supply for sales
.
It is understood that this is also the 15 times that Pien Tze has raised the price of Pien Tze Huang products in 15 years
.
The industry believes that the increase in cost prices is the reason for the recent surge in the price of Chinese medicine products.
However, it is not known whether the overall price increase of Chinese medicine companies will usher in a wave of price increases.
However, from the financial data, many Chinese medicine companies are already facing considerable performance pressure
.
For example, Tongrentang's Angong Niuhuang Wan belongs to the cardiovascular and cerebrovascular sector.
This sector will bring a revenue of 3.
004 billion yuan in 2020, but in 2020 it will drop 1.
16% year-on-year
.
In terms of overall performance, from 2018 to 2020, Tongrentang's revenue growth rates were 6.
23%, -6.
56%, and -3.
4%, respectively; net profit growth rates were 11.
49%, -13.
12%, and 4.
67%.
We can see that the company's performance is relatively turbulent.
; For another example, the third-quarter 2021 financial report disclosed by China Resources Sanjiu showed that the company achieved revenue of 3.
343 billion yuan in the first nine months, a year-on-year decrease of 2.
7%; realized net profit of 376 million yuan, a year-on-year decrease of 28.
57%
.
China Resources Sanjiu said on the investor interaction platform that the company's revenue and profit declined year-on-year, mainly due to the rapid decline in the anti-infection business in the prescription drug business and the certain decline in traditional Chinese medicine injections
.
Under the new challenges, many Chinese medicine companies are also taking active measures
.
For example, China Resources Sanjiu said on the interactive platform that with the increase in overall costs in recent years, especially the rising cost of raw materials, labor costs, etc.
, while taking into account the acceptance of patients and the company’s alleviation of cost pressure, it has targeted different products and At different stages of the product cycle, the company will also adopt different pricing strategies
.
.
Not long ago, Beijing Tongrentang issued a price adjustment notice.
The selling price of Angong Niuhuang Pills (3 g × 1 pill/box) rose from 780 yuan to 860 yuan, a price increase of about 10%, and the implementation began on December 1
.
According to industry sources, this is the third time that Tongrentang has publicly adjusted the price of Angong Niuhuang Wan in the past 20 years
.
In 2012, the price of Angong Niuhuang Wan produced by Tongrentang increased by 60%, from 350 yuan to 560 yuan; in December 2019, Tongrentang Angong Niuhuang Wan increased from 560 yuan to 780 yuan, an increase of about 40%
.
Regarding the reason for the price increase this time, Beijing Tongrentang told the relevant media that the main reason is that the price of raw materials for the production of Angong Niuhuang Wan has been rising, coupled with labor costs, so the overall price of the product has also risen
.
It is worth mentioning that not long after the news of the price increase of Angong Niuhuang Pills, another Chinese medicine giant also announced that its Angong Niuhuang Pills had increased the price
.
On December 13, China Resources Sanjiu replied to investors on the interactive platform that due to the continuous increase in overall costs in recent years and other reasons, the ex-factory price of the company's Angong Niuhuang Wan has increased this year
.
Some industry analysts pointed out that Angong Niuhuang Wan consists of 11 medicinal materials.
The main raw materials include bezoar, musk, pearl, cinnabar, realgar, coptis, yellow census, gardenia, turmeric, borneol and buffalo horn concentrate powder
.
Relevant statistics show that among the 11 raw materials mentioned above, 7 have increased their prices in the past year
.
Among them, the price increase of huanglian and turmeric is more than 30%
.
"Bezoar and musk are still rare and precious materials
.
The precious medicinal materials have been soaring in recent years.
At present, 1g of natural bezoar is about 500 yuan, and 1g of natural musk is about 400 yuan, which is equivalent to 400,000-500,000 per kilogram.
The sky-high price above RMB yuan
.
” This person believes that from the perspective of the composition of medicinal materials, the overall increase in product prices caused by the increase in raw material prices is also expected
.
In addition to Angong Niuhuang Pills, in May this year, Pien Tze Huang also raised the price of Pien Tze Huang products, mainly because of the increase in cost prices and the use of limited supply for sales
.
It is understood that this is also the 15 times that Pien Tze has raised the price of Pien Tze Huang products in 15 years
.
The industry believes that the increase in cost prices is the reason for the recent surge in the price of Chinese medicine products.
However, it is not known whether the overall price increase of Chinese medicine companies will usher in a wave of price increases.
However, from the financial data, many Chinese medicine companies are already facing considerable performance pressure
.
For example, Tongrentang's Angong Niuhuang Wan belongs to the cardiovascular and cerebrovascular sector.
This sector will bring a revenue of 3.
004 billion yuan in 2020, but in 2020 it will drop 1.
16% year-on-year
.
In terms of overall performance, from 2018 to 2020, Tongrentang's revenue growth rates were 6.
23%, -6.
56%, and -3.
4%, respectively; net profit growth rates were 11.
49%, -13.
12%, and 4.
67%.
We can see that the company's performance is relatively turbulent.
; For another example, the third-quarter 2021 financial report disclosed by China Resources Sanjiu showed that the company achieved revenue of 3.
343 billion yuan in the first nine months, a year-on-year decrease of 2.
7%; realized net profit of 376 million yuan, a year-on-year decrease of 28.
57%
.
China Resources Sanjiu said on the investor interaction platform that the company's revenue and profit declined year-on-year, mainly due to the rapid decline in the anti-infection business in the prescription drug business and the certain decline in traditional Chinese medicine injections
.
Under the new challenges, many Chinese medicine companies are also taking active measures
.
For example, China Resources Sanjiu said on the interactive platform that with the increase in overall costs in recent years, especially the rising cost of raw materials, labor costs, etc.
, while taking into account the acceptance of patients and the company’s alleviation of cost pressure, it has targeted different products and At different stages of the product cycle, the company will also adopt different pricing strategies
.
